The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3

被引：1
|
作者：
O'Shaughnessy, Joyce [1 ]
Goetz, Matthew P. [2 ]
Sledge, George W. [3 ]
Martin, Miguel [4 ,5 ]
Lin, Yong [6 ]
Forrester, Tammy [6 ]
Smith, Ian C. [6 ]
Di Leo, Angelo [7 ]
Johnston, Stephen [8 ]
机构：
[1] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA
[2] Mayo Clin, Rochester, MN USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Geicam, Inst Invest Sanitaria Gregorio Maranon, Ciberonc, Madrid, Spain
[5] Univ Complutense, Madrid, Spain
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] Hosp Prato, Prato, Italy
[8] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT099
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT099
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies
    Goetz, Matthew P.
    O'Shaughnessy, Joyce
    Sledge, George W., Jr.
    Martin, Miguel
    Lin, Yong
    Forrester, Tammy
    Mockbee, Colleen
    Smith, Ian C.
    Di Leo, Angelo
    Johnston, Stephen
    CANCER RESEARCH, 2018, 78 (04)
  • [2] Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
    Stephen Johnston
    Joyce O’Shaughnessy
    Miguel Martin
    Jens Huober
    Masakazu Toi
    Joohyuk Sohn
    Valérie A. M. André
    Holly R. Martin
    Molly C. Hardebeck
    Matthew P. Goetz
    npj Breast Cancer, 7
  • [3] Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
    Johnston, Stephen
    O'Shaughnessy, Joyce
    Martin, Miguel
    Huober, Jens
    Toi, Masakazu
    Sohn, Joohyuk
    Andre, Valerie A. M.
    Martin, Holly R.
    Hardebeck, Molly C.
    Goetz, Matthew P.
    NPJ BREAST CANCER, 2021, 7 (01)
  • [4] Toxicity of abemaciclib plus endocrine therapy for HR+HER2-advanced breast cancer in Caucasian patients - pooled analysis from MONARCH 2 and 3 trials
    Kisro, J.
    Ettl, J.
    Korfel, A.
    Herbertz, S.
    Stoffregen, C.
    Huober, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 162 - 162
  • [5] Abemaciclib plus fulvestrant or nonsteroidal aromatase inhibitor in participants with HR+, HER2-breast cancer - A pooled analysis of the endocrine therapy-naive participants with measurable disease in MONARCH 2 and MONARCH 3
    Goetz, Matthew P.
    Trujillo, Jose Luis Gonzalez
    Toi, Masakazu
    Huober, Jens
    Llombart-Cussac, Antonio
    Zhang, Wei
    Knoderer, Holly
    Haddad, Nadine
    Van Hal, Gertjan
    Sledge, George W., Jr.
    CANCER RESEARCH, 2022, 82 (04)
  • [6] Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials
    Franzoi, M. A.
    Ameye, L.
    Eiger, D.
    Piccart, M.
    Brandao, M. D. R. A.
    Ponde, N.
    Desmedt, C.
    Di Cosimo, S.
    Paesmans, M.
    Caparica, R.
    Kotecki, N.
    Lambertini, M.
    De Angelis, C.
    Awada, A. H.
    de Azambuja, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S71 - S71
  • [7] Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies
    Di Leo, Angelo
    Dickler, Maura
    Sledge, George W.
    Toi, Masakazu
    Forrester, Tammy
    Nanda, Shivani
    Koustenis, Andrew
    Bourayou, Nawel
    Johnston, Stephen
    CANCER RESEARCH, 2018, 78 (04)
  • [8] Abemaciclib plus fulvestrant in participants with HR+/HER2-advanced breast cancer: A pooled analysis of the endocrine therapy naive (EN) participants in MONARCH 2
    Luis-Gonzalez Trujillo, J.
    Escobar Gomez, M.
    Sohn, J. H.
    Im, Y-H.
    Wang, H-C.
    Cussac, A. Llombart
    Zhang, W.
    Haddad, N.
    Wasserstrom, H.
    van Hal, G.
    Sledge, G. W., Jr.
    ANNALS OF ONCOLOGY, 2021, 32 : S464 - S465
  • [9] Clinical outcomes of patients with PIK3CA mutations in circulating tumor DNA: Update from the MONARCH 2 study of abemaciclib plus fulvestrant
    Tolaney, Sara M.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Grischke, Eva-Maria
    Soliman, Hatem
    Litchfield, Lacey M.
    Wang, Hong
    Wijayawardana, Sameera R.
    Jansen, Valerie M.
    Sledge, George W.
    CANCER RESEARCH, 2020, 80 (16)
  • [10] Clinical characteristics of patients (pts) with complete response (CR) to abemaciclib-based endocrine therapy (ET) in MONARCH 2 (M2) and MONARCH 3 (M3)
    Huober, J.
    Grischke, E-M.
    Guiu, S.
    Tueux, N. Quenel
    Chouaki, N.
    Stoffregen, C.
    Korfel, A.
    Lerebours, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S67 - S68
12345